Celldex Therapeutics (CLDX) is emerging as a biotech name to watch, driven by its innovative antibody pipeline and promising late-stage trials. With strong clinical progress, a solid cash position, and growing investor confidence, the company is positioning itself at the forefront of treatments for severe allergic and inflammatory diseases.
Company Overview
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com